The Successful Use of Apixaban in Dialysis Patients with Calciphylaxis Who Require Anticoagulation: A Retrospective Analysis

Am J Nephrol. 2018;48(3):168-171. doi: 10.1159/000491881. Epub 2018 Sep 3.

Abstract

Calciphylaxis is a disease of dermal arteriolar calcification that results in necrosis. It commonly occurs in individuals with end-stage renal disease (ESRD) on hemodialysis and is associated with a high morbidity and mortality. Warfarin use is an identified risk factor. Twenty patients with ESRD on dialysis with calciphylaxis who were treated with apixaban for indications of deep vein thrombosis or atrial fibrillation were identified. There were no reports of thrombosis. Three individuals experienced bleeding requiring a transfusion, and anticoagulation was resumed without further event. Findings suggest that apixaban may be a safe and effective alternative to warfarin in patients with ESRD on dialysis with calciphylaxis.

Keywords: Apixaban; Calcific uremic arteriolopathy; Calciphylaxis; Dialysis; Warfarin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / etiology
  • Calciphylaxis / blood
  • Calciphylaxis / etiology*
  • Factor Xa Inhibitors / administration & dosage*
  • Factor Xa Inhibitors / adverse effects
  • Female
  • Hemorrhage / chemically induced
  • Hemorrhage / epidemiology
  • Humans
  • Kidney Failure, Chronic / complications*
  • Kidney Failure, Chronic / therapy
  • Male
  • Middle Aged
  • Pyrazoles / administration & dosage*
  • Pyrazoles / adverse effects
  • Pyridones / administration & dosage*
  • Pyridones / adverse effects
  • Renal Dialysis
  • Retrospective Studies
  • Treatment Outcome
  • Venous Thrombosis / drug therapy*
  • Venous Thrombosis / etiology

Substances

  • Factor Xa Inhibitors
  • Pyrazoles
  • Pyridones
  • apixaban